Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN?

ISCV charges 0.06% versus IWN’s 0.24% and offers a higher 1.9% dividend yield versus 1.5%, while IWN delivered stronger 1-year total return at 48.6% versus 37.5%. Over five years, ISCV had a slightly smaller maximum drawdown (-25.34% vs. -26.71%), but IWN remains larger and more liquid with $13.4 billion in AUM versus $644.5 million for ISCV. The article is a comparative ETF analysis with no new catalyst, so the likely market impact is limited.

Analysis

The real edge here is not which ETF has the better headline stats, but which vehicle better monetizes a small-cap value factor regime that is still being driven by higher-for-longer real rates and continued dispersion in balance-sheet quality. The cheaper wrapper with the slightly better yield should outperform on a long horizon if factor returns are only moderate, because in a low-conviction market the fee gap compounds faster than the small tracking differences. That said, the larger fund’s liquidity premium matters if the factor re-rates violently: in a sharp risk-off or factor-reversal month, tighter spreads and deeper creation/redemption capacity usually dominate marginally better expense ratios.

The holdings overlap is low enough that this is not just a fee arbitrage; it is also a sector-tilt decision. The more concentrated exposure to financials in the larger fund makes it more sensitive to credit conditions and curve changes, while the alternative’s more idiosyncratic top holdings increase single-name dispersion. That creates a second-order opportunity: if small-cap value leadership broadens beyond financials and industrial cyclicals, the more diversified, lower-fee structure has a cleaner path to keep outperforming without needing heroic stock selection by the index provider.

The stock-specific signal is modestly constructive for the top constituents, but the bigger implication is for positioning around the ETF wrappers themselves. MRNA and CF are the only names with meaningful positive flow/attention read-through from the portfolio composition; the rest are too small to matter individually. The consensus is likely underestimating how much of the relative return differential will come from drag reduction rather than alpha — in a 12-24 month window, 18 bps of fee advantage is meaningful enough to offset a decent chunk of liquidity disadvantage unless the fund is used for tactical trading.

Key Decisions for Investors

• Long ISCV / short IWN in a 6-12 month pair trade, sized modestly: thesis is fee compounding plus slightly better yield should outweigh liquidity discount if small-cap value remains a hold-to-harvest factor rather than a trading vehicle.
• If needing tactical small-cap value exposure for a 1-3 month window, prefer IWN over ISCV despite the higher fee; the tighter trading frictions and better creation depth should matter more around macro events or sharp factor rotations.
• For longer-term allocators, build ISCV on weakness with a 3-6 month horizon and a disciplined rebalance rule; risk/reward improves if real yields stay elevated and the market continues rewarding balance-sheet simplicity.
• Watch MRNA and CF as the only meaningful composition-driven read-throughs; if either weakens on fundamentals, that reduces the chance the cheaper fund’s relative performance gets masked by a few oversized positions.
• Avoid chasing the recent 1-year return gap in IWN; the setup favors mean reversion in wrapper economics, and the incremental upside from liquidity is unlikely to compensate for persistent fee drag unless turnover is high.